First subjects in ph III study with PB006 (proposed Biosimilar to Natalizumab) have been randomized.

Published: 18.11.2019

Our phase III clinical trial (PB006-03-01) entered into the stage when first patients were treated with study medication.

This study is conducted in 7 countries in and outside Europe including Poland. First participants were included in the study at the clinical site in Katowice (Poland).



The study, managed by Hendrik Wessels, Polpharma Biologics Clinical Development team, led by Karsten Roth, Director Clinical Research & Development, is an essential part of the development program for the proposed Biosimilar to Natalizumab.


More information can be found here


written by: Polpharma Biologics

Let’s collaborate and create quality biologics together.

Get in touch for more information.

We use cookies

Polpharma Biologics uses cookies and other similar technologies (hereinafter: cookies) on its webpages and mobile applications (hereinafter, jointly, Website). The user can manage cookies independently by changing the web browser settings. If you do not consent for your personal data to be collected via cookies, you should change your web browser settings or stop using the Website.

Using the Website without changing the web browser settings indicates your acceptance of the use of cookies by Polpharma. Acceptance of the web browser settings indicates your consent to profiling on the basis of the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect lawfulness of any processing activities carried out under consent before its withdrawal.

For more details see the Cookie Policy.